Floatz logo

Sasanlimab

Kidney Neoplasms

NiKang Therapeutics, Inc.monoclonal_antibodyPhase 2Active
C
34/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
19/ 100
Competitive Position
89/ 100

Competitive context

16 Active assets in the Kidney Neoplasms cohort.

Asset / SponsorPhaseRating
Axitinib
Pfizer
Phase 3BB
Ipilimumab
Pfizer
Phase 4BB
Nivolumab
Bristol-Myers Squibb
Phase 4BB
Inno-206
Merck Sharp & Dohme LLC
Phase 2BB
Sorafenib
Pfizer
Phase 3B

View all 50 →

Same molecule, other indications

Sasanlimab is also rated in:

non-small cell lung carcinomaDormant
CC
Indicative ·
41 / 100
View asset →
renal cell carcinomaDormant
C
Indicative ·
39 / 100
View asset →
neoplasmDormant
C
Indicative ·
39 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →